19
total announcements
524404.BO · 15 min delayed
Marksans Pharma Ltd
Marksans Pharma Ltd has announced the voting results of its 34th Annual General Meeting (AGM), where all resolutions were passed with 100% or near 100% voting in favor. The company also declared a final dividend of Rs.0.90 per equity share.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced the voting results of its 34th AGM, with all resolutions passed with 100% approval from promoters and 99.98-100% approval from public shareholders. The company also declared a final dividend of Rs.0.90 per equity share.
Marksans Pharma Ltd
Marksans Pharma Ltd held its 34th Annual General Meeting (AGM) on August 27, 2026, through video conferencing. The meeting was attended by shareholders, directors, and other officials. The Chairman delivered a speech, and members expressed satisfaction with the company's performance and provided suggestions.
Marksans Pharma Ltd
Marksans Pharma Ltd has informed about its ESG rating by Crisil ESG Ratings & Analytics Ltd, which has assigned an ESG Score of 56 for Fiscal 2026.
Marksans Pharma Ltd
Marksans Pharma Ltd reported Q1 FY27 financial results, with revenue up 35.6% YoY to INR841 crores, EBITDA at INR213 crores, and PAT at INR159 crores. The company highlighted its strong performance in Europe, with revenue growth of 74.7% YoY, and expansion into new markets such as Canada and Australia.
Marksans Pharma Ltd
Marksans Pharma Ltd has uploaded the audio recording of its investor/analyst conference call on Q1 FY 27 financial results on its website.
Marksans Pharma Ltd
Marksans Pharma Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Marksans Pharma Ltd
Marksans Pharma Ltd reported Q1FY27 financial results, with record profitability and cash balance crossing ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 crore. The company's UK & Europe business delivered its highest-ever quarterly revenue of ₹356 crore, growing 74.7% YoY.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced its Q1 FY 27 financial results, with revenue growing 35.6% YoY to ₹841 cr, EBITDA increasing 112.8% to ₹213 cr, and PAT rising 173.9% to ₹159.4 cr. The company has also reported an all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore. The UK & Europe segment delivered its highest-ever quarterly revenue of ₹356 crore, growing 74.7% YoY.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the company's management and board of directors approving the results. The results are available on the company's website and have been reviewed by the independent auditor, M/S K A & Associates LLP, with an unmodified opinion.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The results are available on the company's website.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced the newspaper publication for its 34th Annual General Meeting Notice, with the meeting to be held through VC/OAVM facility without physical presence of members.
Marksans Pharma Ltd
Marksans Pharma Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per the provisions of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Marksans Pharma Ltd
Marksans Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26 and announced the 34th Annual General Meeting to be held on August 27, 2026. The report includes the company's financial statements, auditor's report, and a forward-looking statement.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced the 34th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The meeting will consider and adopt the audited standalone and consolidated financial statements for the FY 2025-26, declare a final dividend of 90% on equity shares, and re-appoint Mrs. Sandra Saldanha as a Whole-time Director. The company will also consider and pass a resolution for the re-appointment of Mrs. Saldanha with a remuneration package.
Marksans Pharma Ltd
Marksans Pharma Ltd has scheduled a conference call on August 13, 2026, to discuss its unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Ltd
Marksans Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve Quarterly Results For The Quarter Ended June 30, 2026.
Marksans Pharma Ltd
Marksans Pharma Ltd has published a newspaper advertisement regarding the 34th Annual General Meeting scheduled to be held on August 27, 2026, through VC/OAVM facility.
Marksans Pharma Ltd
Marksans Pharma Ltd has initiated a 'Saksham Niveshak' campaign, a second 100-day drive, following guidance from the Ministry of Corporate Affairs (MCA). The campaign aims to assist shareholders in updating their KYC details, registering nominations, and claiming unclaimed dividends from Financial Year 2018-19 onwards. This proactive measure seeks to prevent these unclaimed dividends from being transferred to the Investor Education and Protection Fund (IEPF). Shareholders are encouraged to contact the Company's Registrar and Transfer Agent (RTA) or Company Secretary for assistance before the deadline of July 08, 2026.